Antipsychotic medication for childhood-onset schizophrenia by Kennedy, Eilis et al.
 
 
Tavistock and Portman E-Prints Online 
 
  
 
 
JOURNAL ARTICLE 
 
 
Original citation: 
Kennedy, Eilis and Kumar, Ajit and Datta, Soumitra (2007) Antipsychotic medication 
for childhood-onset schizophrenia. Schizophrenia Bulletin, 33 (5). pp. 1082-1083. 
ISSN 0586-7614 
 
 
© 2007  Eilis Kennedy 
 
This version available at: http://taviporttest.da.ulcc.ac.uk/ 
 
Available in Tavistock and Portman E-Prints Online: Oct 2009 
The Trust has developed the Repository  so that users may access the clinical, 
academic  and research work of the Trust. 
 
 Copyright © and Moral Rights for the papers on this site are retained by the 
individual authors and/or other copyright owners. Users may download and/or print 
one copy of any article(s) in Tavistock and Portman E-Prints Online to facilitate 
their private study or for non-commercial research. You may not engage in further 
distribution of the material or use it for any profit-making activities or any 
commercial gain. You may freely distribute the URL 
(http://taviporttest.da.ulcc.ac.uk/) of  Tavistock and Portman E-Prints Online. 
 
This document is the published version of ‘Antipsychotic medication for childhood-
onset schizophrenia’.   It is freely available online.  You are encouraged to consult 
the remainder of this publication if you wish to cite from it. 
 
 
 
 
 
Antipsychotic Medication for Childhood-Onset Schizophrenia
Eilis Kennedy1,2, Ajit Kumar3, and Soumitra S. Datta4
2Child andFamilyDepartment, TavistockClinic, 120Belsize Lane,
LondonNW35BA,UK; 3Academic unit of Psychiatry, Leeds,UK;
4Department of Child and Adolescent Psychiatry, Royal
Manchester Children’s Hospital, Manchester, UK
Key words: cochrane/childhood onset/schizophrenia
Childhood-onset schizophrenia is defined as schizophre-
nia with onset prior to the age of 13 years. Although it is
rare, those who suffer from schizophrenia at an early age
appear to have a clinically severe form of the illness with
a poor long-term prognosis. Antipsychotic medication is
one way of managing this rare but serious mental illness.
A new Cochrane review examines antipsychotic medica-
tion for childhood-onset schizophrenia.1
Objective
To determine the effects of antipsychotic medication in
the treatment of childhood-onset schizophrenia.
Search Strategy
We searched the Cochrane Schizophrenia Group Trials
Register (February 2007), inspected references of all iden-
tified studies for further trials, and contacted relevant
pharmaceutical companies and authors of trials for addi-
tional information.
Selection Criteria
We included all randomized clinical trials involving
children and young people with a diagnosis of childhood-
onset schizophrenia (ie, with a diagnosis of schizophre-
nia before the age of 13) comparing any antipsychotic
drug with another antipsychotic or placebo.
Data Collection and Analysis
Studies were reliably selected, quality assessed, and data
extracted. For homogenous dichotomous data, we calcu-
lated random effects, relative risk (RR) and its 95% con-
fidence interval (CI), and, where appropriate, number
needed to treat on an intention-to-treat basis. For normal
continuous data, we calculated the weighted mean
difference (WMD).
Main Results
From a total of 2062 citations, 6 relevant trials were iden-
tified. These studies were small (total N = 256 partici-
pants) and short (all duration 12 weeks or less) and
reported data for 3 comparisons (atypical vs. typical,
atypical vs atypical, and typical vs. typical antipsychotic
drugs), only one of which (atypical vs. typical) was to sug-
gest differences between treatment groups.
A few results from one study favored the atypical
antipsychotic clozapine over haloperidol for treating
treatment-resistant childhood-onset schizophrenia (n = 21,
WMD children’s global assesment scale 17.00, CI 7.74–
26.26; n = 21, WMD Bunney-Hamburg Psychosis Rating
Scale 3.60, CI 6.64 to 0.56). Participants on cloza-
pine, however, were 3 times more likely to have drowsi-
ness (1 randomized controlled trial [RCT], n = 21, RR 3.3,
CI 1.2–8.9, number needed to harm 2, CI 2–17) and half
of the children receiving clozapine in this small short
study experienced neutropenia (1 RCT, n = 21, RR 12,
CI 0.75–193; figure 1).
Reviewers’ Conclusions
There are few relevant trials and, presently, little conclu-
sive evidence regarding the effects of antipsychotic med-
ication for those with the rare but difficult problem of
very early-onset schizophrenia. Some benefits were iden-
tified in using the atypical antipsychotic clozapine com-
pared with haloperidol, but the benefits were offset by an
increased risk of serious adverse effects.
Implications for Practice
As yet there are few data to support the use of one an-
tipsychotic medication over another in the treatment
of schizophrenia with onset in childhood. The superiority
of atypical antipsychotic medications over typical anti-
psychotic drugs is not reflected in studies using typical
medications such as chlorpromazine as the comparator
medication, rather than haloperidol. Routine practice
may be best within the context of an evaluative trial.
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Implications for Research
Further RCTs with larger samples and longer treatment
durationareneededtoevaluatetheeffectivenessandsafety
ofantipsychoticmedication in the treatmentof childhood-
onsetschizophrenia.Therehasbeennosignificant increase
in thenumber of trials in the last 3 decades possibly reflect-
ing the challenges of undertaking research with this age
group.Given the relative rarity of childhood-onset schizo-
phrenia, future treatment studies will require multicenter
collaboration and extensive case-finding efforts.
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Fig. 1. Clozapine vs Haloperidol—Neutropenia.
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